Get started
Amarin Corporation plcAmarin Corporation plcAmarin Corporation plc

Amarin Corporation plc

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

AMRN trade ideas

AMRN - All good things to those who wait... Been following this company's progress for over ten years. It is truly remarkable what they have been through to get to where they are now. Bottomline, Vascepa is a blockbuster in the making with incredibly compelling and unprecedented outcomes based clinical trial results which will make this standard of care to a large subset of our population. What is even more compelling is this is a highly pharmacoeconomic argument being a relatively inexpensive therapy with profound positive preventative cardiovascular characteristics and basically zero side-effects. Very surprised one of big pharma has not taken their shot at this company yet, perhaps simply waiting for the final checkmark in the expanded label from the FDA in the Fall. Amazing thing is, they are already approaching a $500 million annual revenue run-rate with limited label and sales force, so projecting $2.5-5 Billion molecule for this with expanded label, expanded sales, and incredibly strong outcomes based clinical data is very possible...would suggest company should/could get taken out at multiple of current stock price over the coming year.
NASDAQ:AMRNLong
by mikebmc
2
My idea for 07-19-2019 $AMRNGood Morning Guys, so for today my favorite is NASDAQ:AMRN , i love the technicals today on this stock, it has broken all moving averages, trend lines, and we have some room to move to the down side, i will watch this stock and look for an entry if at the open can break hold below USD18.00, and start moving on my direction. Please be aware that we do not have any significant catalyst so i will be extra careful. Remember that this is for educational purposes only.
NASDAQ:AMRN
by leoamartinez
OPTIONS TRADERS AND TECHNICALS POINT TO BULLISH SURGE IN AMARIN Just because Amarin BIO is up so much don't be scared of, options traders are betting on much higher gains to come, we tend to agree as the chart is setting up extremely bullish with they Price, RSI and Momentum indicator are all approaching the apex/top of ascending triangles. A breakout could come at any time in a stock surrounded with rumour and speculation. It looks a good risk reward long. Alerts are set for move above $22 so as to assess for long entry. COMPANY PROFILE Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
NASDAQ:AMRNLong
by RedHotStocks
AMARIN CORP - NASDAQ: $AMRN Setting-UpAfter breaking to higher ground in 1Q19 and subsequently drifting back down to its original break-out level in the upper teen's, the shares of AMARIN CORP NASDAQ: AMRN are once again starting to show signs of potentially setting-up for another attempt at loftier levels as evidenced in the Daily chart above. While AMRN presently finds itself in drift mode working on its right-side, the stock continues to display favorable technical characteristics trading above all of its important moving averages (20/50/200 DMA's). Although further work is required, it appears that we may just witness a repeat of 1Q whereby buyers once again start to take control of the stock and should such scenario materialize, we suspect that it may have eyes for the $22 - $24 zone once again in the short-term. Thus, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead for signs/clues that a move for greener pastures is underway.
NASDAQ:AMRN
by OptionsGains
$AMRN Options activity coincides with FDA meeting on 31st MayHighly unusual options activity was spotted in the stock of NASDAQ:AMRN on fridays which in turn coincides with a upcoming FDA hearing scheduled for friday the 31st may. The FDA is holding a public hearing on May 31 to discuss potential regulation for cannabis products. The chart of amrn is also setting bullish pre the event, as buyers have returned after the post earnings profit taking. This really does look like a great trade with a good RR. ANALYSTS AVERAGE PRICE TARGET $33 ANALYSTS AVERAGE RECOMMENDATION BUT SHORT INTEREST 8.8% COMPANY PROFILE Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
NASDAQ:AMRNLong
by RedHotStocks